Clinical Trials Browser

Completed × ulixertinib × Other hematologic neoplasm × Clear all

NCT02296242 2019-01-29

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Phase 1/2 Completed

53 enrolled 16 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute